

the vitality of thought is in adventure



CENTER FOR  
**BIOTECHNOLOGY**  
A New York State Center For Advanced Technology  
Supported by the New York State Office of Science,  
Technology and Academic Research (NYSTAR)

*Translating Basic Science into Commercial Opportunities*

# Mission

*To catalyze the translation of basic biomedical sciences into diagnostic and therapeutic technologies that benefit human health and society, and fuel economic growth.*



ideas won't keep



# Director's Message

June 1, 2007

The opportunity to make quantum advances in the prevention, diagnosis and treatment of many of the world's most devastating illnesses is now well within our reach. Scientists throughout the world are making fundamental discoveries regarding the cause and progression of cancer, Alzheimer's disease, obesity, diabetes, cardiovascular disease, and other life-threatening illnesses. Yet the process by which academic-based, biomedical discoveries are translated into the commercial sector is far from optimal. The market pressure on companies to focus on later-stage product candidates has created a significant gap between the intellectual advances of our academic research enterprise and the translational pipeline of the commercial sector.

It is the Center for Biotechnology's vision to help bridge this gap by utilizing the vast intellectual and physical resources of Stony Brook University and Brookhaven National Laboratory to accelerate the discovery, development and translation of next-generation product candidates into the biosciences industry. The collective academic, scientific and intellectual property assets of these Institutions contribute to a vibrant research and development enterprise that fosters innovation on a scale not easily surpassed.

We have already demonstrated the "proof of principle" of our approach by making valuable contributions to the development of several commercial products, including ReoPro™, Periostat®, Cavistat®, the V3D Colon™ virtual colonoscopy, SAFHS™ and Dynamic Motion Therapy™. New York State has recently recognized our work with a \$1.65M, 3-year translational research award that has been matched by corporate investment of \$1.3M. These funds will be used to accelerate the commercialization of several novel product candidates.

We have also recently broken ground on our Center for Biotechnology and Bioengineering, a New York State Strategically Targeted Academic Research (STAR) Center. The STAR Center will be the focal point for our translational research efforts going forward.


These are exciting times, yet the void between academic discovery and the translation of these novel technologies into the commercial sector remains great. With the tremendous research infrastructure of our academic institutions, and an entrepreneurial bioscience industry poised for exponential growth, we have the opportunity to revolutionize how universities participate in the translation of basic science into life enhancing technologies.

We ask for your support in realizing this goal.



**Clinton T. Rubin, Ph.D.**

Director, Center for Biotechnology  
SUNY Distinguished Professor &  
Chair, Department of Biomedical Engineering



something must be done about them

# Economic Impact Summary

2001–2006

<i>Jobs Created</i>	575
<i>Corporate Revenues</i>	\$ 445M
<i>Corporate Savings</i>	\$11.8M
<i>Funds Leveraged</i>	\$ 106M
<i>Economic Impact</i>	\$ 575M

## Economic Impact

Reported on the adjoining page is a five-year summary of economic impact related to the Center for Biotechnology's activities. For the period beginning July 1, 2001 and concluding June 30, 2006, the Center for Biotechnology was responsible for the creation of 575 new jobs, supported the generation of approximately \$445M in new corporate revenues, contributed to \$11.8M in corporate savings, and leveraged \$106M in federal and private funding for translational research. Total economic impact related to the State's \$5M investment in the Center for Biotechnology for this five-year period is approximately \$575M. A detailed economic impact statement appears in Appendix A.

vitality of  
thought



# Investments in Technology Development

2001–2006

<i>Number of Projects Funded</i>	29
<i>Center Investment</i>	\$818,032
<i>Corporate Investment</i>	\$465,069



## Technology Development

The Center for Biotechnology continues to serve as a valuable resource to New York's bioscience industry. Over the last five years the Center for Biotechnology has entered into 308 collaborations with as many as thirty-four different New York State bioscience companies each year. Thirty percent of these collaborations involved small (less than 250 employees) New York State bioscience companies. Cumulative investment in sponsored research collaborations by New York State companies between 2001–2006 totals \$6.6M. An annual breakdown of our corporate sponsored research expenditures appears in Appendix B.

### Corporate Sponsored Research Expenditures

2001–2006

*308 Projects*

*\$6.6M in NYS Corporate Expenditures*

*30% of Projects Involved Small NYS Companies*

Further, the Center cost-shares collaborative research and development projects between small, New York biomedical companies and faculty as a means of accelerating discovery and development of technologies that will have a predetermined path to market. Since 2001 the Center for Biotechnology has invested \$818K in twenty-nine promising research projects through this process, leveraging \$465K in corporate investment from small, New York State corporate partners. A detailed summary of annual technology development investments and corporate clients is located in Appendix C and on the back cover respectively.

is in adventure



## Technology Pipeline

The Center for Biotechnology invests significant effort into proactively identifying promising technology, and through a highly targeted process adding value that will facilitate the generation of new intellectual property, licensing, strategic partnerships, and/or new company formation in New York State. These investments over time have resulted in an active pipeline of approximately fifty-six commercially valuable technologies at various stages of development. Forty-four of these have had patents filed or issued, and of these twenty-four have been licensed. License income related to these agreements approaches \$5.2M. These technologies, and their development status, are listed below.

Investigator	Technology
Chen, Wen-Tien	Cancer Invasiveness Analyzer and Use Thereof
Bingham, Paul	Cancer Chemotherapy Targeting Tumor Specific Pyruvate Dehydrogenase Complex
Wishnia, Arnold; Wagshul, Mark	MRI Using Hyperpolarized I29Xe
Kaufman, Arie	3D Virtual Endoscopy: For Non-Invasive Examination of Hollow Human Organs or Other Objects
Prestwich, Glenn	Disulfide Containing Hyaluronic Acid Hydrogels and Modification of Carboxylates in Hyaluronic Acid Oligosaccharides
Ojima, Iwao	Taxoid Anti-Tumor Agents & Pharmaceutical Composition and Process for the Preparation of Taxane
Bell, Thomas	Anti-Viral Triaza Compounds
Luft, Benjamin	Borrelia Burgdorferi Recombinant Outer Surface Membrane Proteins with a Single Amino-Promimal Cystein Residue
Ojima, Iwao	Anti-Tumor Compounds, Pharmaceutical Compositions, Methods for Preparation Thereof & for Treatment
Sieburth, Scott	Silanol Enzyme Inhibitors
Bell, Thomas	Reagents and Sensors for Urea, Guanidines and Amidines
Fields, Stanley	Two Hybrid Technology to Detect Protein-Protein Interaction and In Vivo Detection of Protein-Peptide Interactions
Kleinberg, Izzie	Salivary Stimulant
Erichsen, Jonathan	Monoclonal Antibody to Fragment C of Tetanus Toxin
Levine, Joel	Mouse Monoclonal Antibody Directed Against Receptor Tyrosine Phosphatase Beta and Neurocan
Carter, Carol	FS II—A Plasmid that Encodes for HIV-I Proteins that Can Be Isolated and Purified in Their Native Form
Trimmer, James	Monoclonal Antibodies
Coller, Barry	Thrombo-erythrocytes
Dhadwal, Harbans	Method & Apparatus for Determining the Physical Characteristics of Ocular Tissue
Soroff, Harry; Pollak, Stan	Sternal Band
Reinstein, Lawrence E.	Automated Radiotherapy Quality Assurance System: An Image Based Quality Assurance Phantom w/Integrated Software for Automated Radiation Beam Analysis, etc.
Chu, Benjamin	Controlled Post-Treatments of Electrospun Membranes to Generate New Morphology and Improve Properties, Bioabsorbable Membranes for the Prevention of Post-Operative Adhesions, and for Cell Delivery Applications
Chen, Weiliam	Biodegradable Polymer Device for Preventing Atrial Fibrillation
Kleinberg, Izzie	Anti-Caries Confection Development
Kaufman, Arie	System and Method for Performing a Three-Dimensional Virtual Examination, Navigation and Visualization
Wimmer, Eckard	Nonpathogenic Polio Recombinants as Therapy for Malignant Brain Tumors
McLeod, Kenneth J.	Methods and Means of Physiologic Vibration Quantifications
Chu, Benjamin	A New Separation Medium for Capillary Electrophoresis
Chu, Benjamin	A New Class of Polymer Solution for Separation of Charged Macromolecules by Means of Electrophoresis
Citovsky, Vitaly	Protein-DNA Complexes as a System for Efficient Delivery of DNA into the Cell Nucleus and a Genetic Screen for Protein Nuclear Import and Export
Citovsky, Vitaly	A Genetic Screen for Protein Nuclear Import and Export
Mishra, Prateek	SBMICS: Stony Brook Medical Image Consultation System
Malbon, Craig	Vector for Antisense RNA Expression in Hybrid mRNAs Driven by Tissue-Specific Promoters
Rokita, Steven	Reactive Appendages for Triplex Inhibition of Gene Expression
Kaufman, Arie	Apparatus & Method for Eye Tracking Interface
Burrows, Cynthia	Cleavage of DNA and Oligonucleotides Using Macrocyclic Nickel (II) Complexes
Golub, Lorne	Chemically Modified Non-Antibacterial Tetracycline Analogs as New Anti-Fungal Agents
Qin, Yi-Xian	Scanning Confocal Acoustic Diagnostic for Bone Quality
Johnson, Roger	Nonsubstituted Adenyl as ProDrug Regulators of Cell and Tissue Function
Clark, Richard	A Fibrinogen Preparation for Wounds
Chon, Ki	Wireless Health Monitors
Galan, Jorge	Development of a System for Efficient Secretion of Recombinant Proteins in Salmonella Thyphimurium
Fisher, Paul	A Simple Method for Purification and Functional Testing of Cloned Proteins that Involves Specific Binding to Chemically Derivatized Cellulose
Bingham, Paul	Lipoic Acid Derivatives and Their Use in Treatment of Disease

# Pipeline Summary

<i>Technologies</i>	56
<i>Patents Filed or Issued</i>	44
<i>Licenses</i>	24
<i>License Income</i>	\$5.2M

Disclosure	Patent	License	Status
✓	✓	✓	New Company Formation (Vitatex Inc.)
✓	✓	✓	New Company Formation (Cornerstone Pharmaceuticals)
✓	✓	✓	Licensed (Magnetic Imaging Technology)
✓	✓	✓	New Company Formation (Viatronix Inc.)
✓	✓	✓	New Company Formation (Clear Solutions Biotech Inc.)
✓	✓	✓	Licensed (Aventis Pharmaceuticals)
✓	✓	✓	Licensed (RCT)
✓	✓	✓	New Company Formation (Brook Biotechnologies Inc.)
✓	✓	✓	Licensed (Indena Pharmaceuticals)
✓	✓	✓	Licensed (Amedis Pharmaceuticals)
✓	✓	✓	Licensed Multiple Licensees
✓	✓	✓	Licensed Multiple Licensees
✓	✓	✓	Licensed (Ortek)
✓	✓	✓	Licensed (Boehringer Mannheim)
✓	✓	✓	Licensed
✓	✓	✓	Licensed
✓	✓	✓	Licensed
✓	✓	✓	Licensed (Ariad)
✓	✓	✓	Licensed (INFOSYS)
✓	✓	✓	Licensed (Stony Brook Surgical)
✓	✓	✓	Licensed (Nuclear Associates)
✓	✓	✓	New Company Formation (STAR)
✓	✓	✓	New Company Formation (EndoMedix Inc.)
✓	✓	✓	Licensed (Ortek)
✓	✓		
✓	✓		NCI sponsored clinical trial
✓	✓		
✓	✓		License option in negotiation
✓	✓		
✓	✓		
✓	✓		
✓	✓		
✓	✓		
✓	✓		
✓	✓		
✓	✓		License option
✓	✓		New Company Formation (AcousticScan)
✓	✓		
✓	✓		New Company Formation (NeoMatrix Formulations)
✓	✓		New Company Formation (Ki Hi-Tech)
✓	✓		
✓	✓		
✓	✓		

## New Company Formation

The Center for Biotechnology's technology development initiative focuses on the discovery and development of technologies most likely to impact the New York State economy. Particular emphasis is placed on the development of platform technologies that have the potential to support new company formation. Eighteen technologies related to, or directly supported by the Center, have been the foundation for new company formation:

**AcousticScan**—medical diagnostic for osteoporosis  
**Affinimark**—medical diagnostics  
**Brook Biotechnology**—medical diagnostics  
**Clear Solutions Biotech**—biopolymers for various medical applications  
**Clearview Patient Safety Products**—blood drawing device  
**Collagenex**—therapeutics  
**Cornerstone Pharmaceuticals**—novel anti-cancer therapeutics  
**EndoMedix**—vascular & wound healing technologies  
**Exogen**—bone healing system  
**Juvent**—medical device for the prevention and treatment of osteoporosis  
**Ki Hi-Tech**—wireless health monitors  
**NeoMatrix Formulations**—novel wound healing, cosmetic, and anti-angiogenesis products  
**Ortek Therapeutics**—treatments for dental disorders  
**Stony Brook Biotechnology**—medical devices and therapeutics  
**Stony Brook Technology & Applied Research (STAR)**—tissue engineering technologies  
**Vasomedical**—external counterpulsation for treatment of angina  
**Viatronix**—virtual colonoscopy & medical diagnostics  
**Vitatex**—novel anti-cancer therapeutics

## New Products

Since 1983 the Center for Biotechnology has been focused on the discovery, development, translation and commercialization of novel, commercially significant technologies. As evidence of our “bench to the bedside” research programs, the Center has contributed to the development of several commercial products that have had a positive impact on human healthcare along with advances in basic and applied research.

- ReoPro™
- Periostat®
- Oracea®
- Proclude®
- Denclude®
- Cavistat®
- Enhanced External Counterpulsation (EECP®)
- Vita-Assay™
- Dynamic Motion Therapy™
- V3D Colon™ virtual colonoscopy
- Two-Hybrid Technology
- EXOGEN™ Bone Healing System
- Dynamic Infrared Imaging Technology (DIRI®)



## Investments in Infrastructure

A cornerstone of the Center for Biotechnology's success has been its investment in the development of infrastructure to support industry growth. These investments have had a profound impact on the industry, and serve as a foundation on which to build long term.

### Long Island High Technology Incubator (LIHTI)

The Center for Biotechnology's role as founder of the Long Island High Technology Incubator Program on the campus of Stony Brook University in 1986 had a significant effect on both the academic culture as well as on the nascent, biotechnology industry sector. The 60,000 square foot facility, located adjacent to the Health Sciences Center on campus, has served as a model for other incubation programs nationwide.

### New York Biotechnology Association (NYBA)

The Center for Biotechnology has been actively involved in the evolution of New York's biotechnology industry since its designation as a Center for Advanced Technology in 1983. In 1990 it joined with other local leaders to form the New York Biotechnology Association, a not-for-profit trade association dedicated to the development and growth of New York State-based biotechnology related industries and institutions. With more than 260 member companies, NYBA serves as an advocate on behalf of the industry and provides access to a network of professional services that support company growth.

### Long Island Life Sciences Initiative (LILSI)

The Long Island region represents the largest bioscience industry cluster in New York State. The Long Island Life Sciences Initiative was founded by the Center for Biotechnology and local industry leaders in 2001 to represent the specific interests of the region's life science industry sectors.

### NY Bioscience Council

The Center for Biotechnology participated in the formation of a New York Bioscience Council with the goal of integrating and unifying regional biosciences initiatives towards a common state-wide economic development agenda. The New York Loves BIO campaign, a statewide marketing initiative focused on enhancing the global perspective of New York's Bioscience activities, was started by the NY Bioscience Council.

ideas won't keep



## Workforce Development

The opportunities that exist within the life sciences to address some of the most devastating human diseases and conditions will require a highly educated, scientifically trained workforce. The Center for Biotechnology's Workforce Development Initiative has implemented several programs to enhance undergraduate and graduate student education, and to help increase the productivity of the Industry's current workforce.

### Department of Biomedical Engineering

The Center for Biotechnology played a fundamental role in the establishment of the Department of Biomedical Engineering at Stony Brook University in December 2000. It is the first BME department in the entire 64-campus SUNY system to offer a Bachelor's of Engineering (B.E.) in Biomedical Engineering degree and an M.S. and Ph.D. in Biomedical Engineering. The department now has 17 core faculty members with sponsored research expenditures approaching \$6M annually.

### Fundamentals of the Bioscience Industry

The Fundamentals of the Bioscience Industry Program provides graduate students, post docs, and incumbent employees with a comprehensive understanding of the bioscience business environment. The Program is fully taught by industry executives, and provides an in-depth introduction to life science product development cycles, regulatory practices, financial models, managerial challenges, and corporate culture. The Program is complimented by a highly interactive mentoring program, the BIO Mentor eNetwork, that allows students participating in Center programs to access our extensive network of life science industry professionals.

### Helix Award

The James D. Watson Helix Award was founded by the Center for Biotechnology at Stony Brook University in 1996. It was created to celebrate the goals of the bioscience industry, to preserve and enhance human life through continued innovation in the life sciences. The James D. Watson Helix Award symbolizes the true entrepreneurial spirit and commercial accomplishments of the biotechnology industry and is now regarded as the biotechnology industry's most prestigious recognition of corporate excellence.



something must  
be done

## New York's Bioscience Industry

New York has been recognized as an emerging leader in the biotechnology industry with large investments in facilities, infrastructure, and R&D.

- 1st in the nation as the top growth state in the Biotechnology sector. *Business Facilities Magazine*, July, 2006
- 2nd in the nation in biotechnology R&D expenditures, totaling \$1.9B, in 2003. *Office of the State Comptroller; Report 11-2005*
- 3rd in the nation with employees in the Biotechnology sector in 2003. *Milken Institute*, 2003
- 4th in the nation in total venture capital investments at \$1.1B. *AeA's Cyberstates 2006: A State-by-State Overview of the High-Technology Industry*, 2005

Recent FDA approvals of treatments by New York-based companies include:

- **Acorda** (Hawthorne, NY)—2002: Zanaflex®
- **Bausch & Lomb** (Rochester, NY)—2004: Zylet®; 2005: Retisert™
- **Bristol-Myers Squibb** (Syracuse, NY)—2001: Definity®; 2002: Tequin™, Zerit™ XR®, Sustiva®; 2003: Reyataz®; 2005: Baraclude®; 2006: Orenicia®, Sprycel®
- **Forest Laboratories** (New York, NY)—2002: Lexapro®; 2003: Namenda®; 2004: Campral®, Combunox®
- **Imclone** (New York, NY)—2004: Erbitux®
- **OSI Pharmaceuticals** (Melville, NY)—2004 & 2006: Tarceva®
- **Pfizer** (New York, NY)—2001: Zyrtec®; 2002: Geodon®, Zithromax®, Sustiva®; 2004: Depo-Provera®, Lyrica®; 2005: Zmax™, Revatio™, Cardura XL®; 2006: Eraxis™, Sutent®, Exubera®

Investments into New York's infrastructure, R&D capabilities, and expansion of funding opportunities and tax incentives are helping New York's vibrant biotechnology industry continue to grow by attracting, developing and retaining life sciences companies with products at all different stages of development.

about them



## Support for Industry

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), one of only 70 institutions in the country to be designated a Type I Research Institution by the Carnegie Foundation, the highest distinction granted to fewer than two percent of all colleges and universities nationwide. In partnership with Batelle, SBU co-manages Brookhaven National Laboratory (BNL), joining an elite group of universities—including Berkeley, University of Chicago, Cornell, MIT, and Princeton—that oversee federal laboratories.

The formal relationship between BNL and SBU, and their close proximity to each other, allows a marriage of the tremendous basic and applied research capabilities of a federal laboratory with the clinical and translational research capabilities of a major research university and medical center. Specialized resources include:

- Health Sciences Center and Medical School
- 540-bed, tertiary care hospital and trauma center
- 350-bed Veterans Home
- Dental School and Dental Care Center
- 246 acre Research Park
- 60,000 ft<sup>2</sup> Business Incubator
- STAR Center in Biotechnology & Bioengineering
- Center of Excellence in Wireless & Information Technology
- Advanced Energy Center
- Center for Computational Sciences (largest super computer in the world for non-classified research)

**To support entrepreneurial activities the Center provides a variety of “value added” services to New York State bioscience ventures and faculty including:**

- Access to faculty expertise and specialized research facilities
- Access to the Long Island High Technology Incubator
- Funding programs to accomplish technical goals
- Commercial assessment of selected technologies
- Development of critical path management strategies
- Hands-on technical support
- Exploration of external financing opportunities
- Assistance in applying for grants, including federal SBIR/STTRs
- Employee training



## Financial Summary

2001–2006

The Center for Biotechnology is eligible for up to \$1M in State funding based on its ability to generate matching investment from industry, federal sources, and our host institution, Stony Brook University. The first \$750,000 in State funding must be matched equally, \$1:\$1. Amounts provided by NYSTAR in excess of \$750,000 must be matched \$2:\$1, for a total match requirement of \$1.25 million annually. At least twenty-five percent of this match must be cash from New York State Companies to support the Center's NYSTAR-approved activities.

NYSTAR funds may be used for faculty, staff, graduate student and undergraduate salaries or stipends, purchase of equipment and supplies, travel associated with business development, and subcontracts to not-for-profit partner organizations. Salary-related expenses (salary, fringe, & IDC) continue to constitute the largest expenditure category for both the NYSTAR and corporate investments in the Center, representing approximately 75% of the total. The majority of the Center for Biotechnology's non-salary related outreach and workforce development expenses, including costs associated with our business development activities and industry events are captured under "Other". All expenditures are reviewed by NYSTAR on a semi-annual basis.

## Financial Report

	2001–2002		2002–2003		2003–2004		2004–2005		2005–2006		Totals
	NYSTAR	Corp	NYSTAR	Corp	NYSTAR	Corp	NYSTAR	Corp	NYSTAR	Corp	
Salary	\$506,265	\$ 906,194	\$552,898	\$ 749,646	\$ 542,385	\$ 715,853	\$524,166	\$362,009	\$ 518,690	\$ 735,657	\$ 6,113,763
Fringe	\$143,396	\$ 209,117	\$153,792	\$ 228,883	\$ 171,709	\$ 218,335	\$172,975	\$105,791	\$ 178,684	\$ 225,721	\$ 1,808,403
IDC	\$ 96,393	\$ 166,941	\$106,003	\$ 145,290	\$ 111,267	\$ 140,129	\$104,571	\$ 70,170	\$ 104,606	\$ 144,206	\$ 1,189,576
Equipment	\$ 47,326	\$ 35,091	\$ 0	\$ 23,181	\$ 16,330	\$ 0	\$ 0	\$101,867	\$ 6,392	\$ 102,367	\$ 332,554
Supplies	\$ 52,262	\$ 209,441	\$ 60,570	\$ 187,743	\$ 125,149	\$ 170,272	\$118,487	\$350,776	\$ 97,545	\$ 166,754	\$ 1,538,999
Travel	\$ 5,026	\$ 23,578	\$ 5,738	\$ 36,047	\$ 7,048	\$ 35,078	\$ 5,800	\$ 0	\$ 560	\$ 0	\$ 118,875
Tuition	\$ 0	\$ 2,614	\$ 0	\$ 3,122	\$ 0	\$ 5,655	\$ 0	\$ 0	\$ 8,961	\$ 24,481	\$ 44,833
Other	\$ 86,673	\$ 54,456	\$113,315	\$ 140,877	\$ 144,645	\$ 147,668	\$ 42,250	\$ 0	\$ 109,869	\$ 196,419	\$ 1,036,172
<b>Totals:</b>	<b>\$937,341</b>	<b>\$1,607,432</b>	<b>\$992,316</b>	<b>\$1,514,789</b>	<b>\$1,118,533</b>	<b>\$1,432,990</b>	<b>\$968,249</b>	<b>\$990,613</b>	<b>\$1,025,307</b>	<b>\$1,595,605</b>	<b>\$12,183,175</b>

## Appendix A

### Economic Impact 2001–2006

	2001–2002	2002–2003	2003–2004	2004–2005	2005–2006	Totals
Jobs Created	91	314	82	44	44	575
Corporate Revenues	\$70,122,000	\$83,276,987	\$248,000,000	\$ 8,665,000	\$ 34,882,025	\$444,946,012
Corporate Savings	\$ 1,992,000	\$ 2,351,306	\$ 2,200,000	\$ 2,645,734	\$ 2,596,762	\$ 11,785,802
NY Corp. Research Expenditures	\$ 1,333,817	\$ 1,319,683	\$ 1,262,920	\$ 1,096,168	\$ 1,595,605	\$ 6,608,193
Funds Leveraged (Acquired)	\$ 9,032,791	\$ 4,536,813	\$ 2,100,000	\$ 7,500,000	\$ 82,875,000	\$106,044,604
Licensing Income	\$ 2,518,863	\$ 1,353,883	\$ 625,316	\$ 377,874	\$ 292,871	\$ 5,168,807
Economic Impact	\$84,999,471	\$92,838,672	\$254,188,236	\$20,284,776	\$122,242,263	\$574,553,418

## Appendix B

### Corporate Sponsored Research Expenditures 2001–2006

	2001–2002	2002–2003	2003–2004	2004–2005	2005–2006	Totals
Total Projects	41	84	71	46	66	308
Corporate Sponsored Research Expenditures	\$ 1,333,817	\$ 1,319,683	\$ 1,262,920	\$ 1,096,168	\$ 1,595,605	\$ 6,608,193
NYS Companies	19	34	30	25	27	135
Projects Involving Small NYS Companies	14	22	20	17	19	92

## Appendix C

### Investments in Technology Development 2001–2006

	2001–2002	2002–2003	2003–2004	2004–2005	2005–2006	Totals
# of Projects	5	6	8	1	9	29
Number Involving Small NYS Companies	3	1	2	1	9	16
State Investment	\$ 119,000	\$ 182,650	\$ 191,448	\$ 39,837	\$ 285,097	\$ 818,032
Small Corporate Investment	\$ 64,000	\$ 62,704	\$ 12,281	\$ 38,282	\$ 287,802	\$ 465,069
Patents Issued	4	4	2	11	5	26
Licenses Issued	1	0	0	2	0	3
Total Investment	\$ 183,000	\$ 245,354	\$ 203,729	\$ 78,119	\$ 572,899	\$ 1,283,101

## New York State Corporate Clients

AcousticScan (Stony Brook, NY)  
Acorda Therapeutics (Hawthorne, NY)  
Advanced Biohealing (New York, NY)  
Advanced BioPhotonics (Bohemia, NY)  
Advanced Viral Research (Yonkers, NY)  
Affinimark (Stony Brook, NY)  
AGI Dermatics (Freeport, NY)  
Angion BioMedical (Great Neck, NY)  
Applied DNA Sciences (Stony Brook, NY)  
Avery Biomedical Devices (Commack, NY)  
Bausch & Lomb (Rochester, NY)  
Bayer Corporation (Rexford, NY)  
BioDigital Systems (New York, NY)  
Biomerix Corporation (New York, NY)  
BioLife Solutions (Binghamton, NY)  
Biopeptides (E. Setauket, NY)  
Biophotonics (Stony Brook, NY)  
Biospecifics Technologies (Lynbrook, NY)  
BioWorks (Fairport, NY)  
Bristol-Myers Squibb (New York, NY)  
Chem-Master International (East Setauket, NY)  
Clear View Patient Safety Products (Huntington, NY)  
Collagenex (Stony Brook, NY)  
Cornerstone Pharmaceuticals (Stony Brook, NY)  
Del Pharmaceuticals (Uniondale, NY)  
Dr. Suwelack (Stony Brook, NY)  
Eele Laboratories (Bohemia, NY)  
Ericsson (New York, NY)  
EndoMedix (Stony Brook, NY)  
Estee Lauder Corp. (Melville, NY)  
Evotope Biosciences (Stony Brook, NY)  
Forest Pharmaceuticals (New York, NY)  
Frontier Pharmaceuticals (Farmingdale, NY)  
Garnett McKeen (Islip, NY)  
inGenious Targeting Laboratories (Stony Brook, NY)  
Ion Focus Tech (Stony Brook, NY)  
Ki Hi-Tech (Stony Brook, NY)  
Lawrence Gelb Research Foundation (New York, NY)  
Lifetree Technologies (Great River, NY)  
LIPA (Uniondale, NY)  
Medicine Rules (Stony Brook, NY)  
Nanoprobes (Yaphank, NY)  
Nastech Pharmaceuticals (Hauppauge, NY)  
NeoMatrix Formulations (Stony Brook, NY)  
Nuclear Associates (Hicksville, NY)  
Ortek Therapeutics (Roslyn Heights, NY)  
OSI Pharmaceuticals (Melville, NY)  
Pall Corporation (Port Washington, NY)  
Paradigm Biomedical (New York, NY)  
PersonaDX (Buffalo, NY)  
Pfizer Pharmaceutical (New York, NY)  
Renal Tech LLP (New York, NY)  
Research Testing Laboratory (Great Neck, NY)  
Stony Brook Biotechnology (Stony Brook, NY)  
STAR (Stony Brook, NY)  
Sustained Nano Systems (Great Neck, NY)  
Ultradian Diagnostics (Rensselaer, NY)  
Viatronix (Stony Brook, NY)  
Vitatex (Stony Brook, NY)  
Vasomedical (Westbury, NY)  
Welch Allyn (Skaneateles Falls, NY)  
Wyeth Ayerst (Pearl River, NY)  
XSB (Stony Brook, NY)  
Zeptogen (Buffalo, NY)



CENTER FOR  
**BIOTECHNOLOGY**

A New York State Center For Advanced Technology

*Supported by the New York State Office of Science,  
Technology and Academic Research (NYSTAR)*

Psychology A, 3rd Floor  
Stony Brook University  
Stony Brook, NY 11794-2580  
Tel: 631.632.8521  
Fax: 631.632.8577  
[www.biotech.sunysb.edu](http://www.biotech.sunysb.edu)

The Center for Biotechnology gratefully acknowledges the contributions of the New York State Office of Science Technology & Academic Research, the US Department of Commerce, Stony Brook University, and our industry partners.

Stony Brook is an Affirmative Action/Equal Opportunity Educator and Employer.  
This publication can be made available in an alternative format upon request.

The vitality of thought is in adventure. Ideas won't keep. Something must be done about them.—Alfred North Whitehead